Accent Therapeutics to Highlight Preclinical Data of ATX-559 and ATX-295 at AACR 2025
Shots:
- Accent Therapeutics to present preclinical data of ATX-559 (DHX9 inhibitor) & ATX-295 (KIF18A inhibitor) at AACR 2025
- Presentation will highlight ATX-559’s activity in cancers exhibiting genomic instability & replication stress in in vivo models, incl. dMMR/MSI-H colorectal & BRCA-altered triple-negative breast cancer, plus ATX-295’s activity in ovarian cancer & its relation with whole genome doubling as a sensitivity biomarker
- ATX-559 is being evaluated in P-I/II dose-escalation and expansion trial for advanced or metastatic BRCA-1 and/or BRCA-2-deficient breast cancer or MSI-H and/or dMMR solid tumors while ATX-295 is expected to enter clinical stage in H1’25
Ref: Prnewswire | Image: Accent Therapeutics
Related News:- Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
